证券代码：300246 证券简称：宝莱特 公告编号：2025-057 债券代码：123065 债券简称：宝莱转债 统一社会信用代码：914404006175020946 商事主体类型：其他股份有限公司（上市） 法定代表人：燕金元 成立日期：1993 年 06 月 28 日 广东宝莱特医用科技股份有限公司 关于公司完成工商变更登记的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、概述 广东宝莱特医用科技股份有限公司（以下简称"公司"）分别于 2025 年 7 月 16 日召开的第八届董事会第二十五次会议、2025 年 8 月 1 日召开的 2025 年第二 次临时股东大会，审议通过了《关于增加公司注册资本及修订〈公司章程〉的议 案》。具体内容详见公司于 2025 年 7 月 17 日于指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于增加注册资本及修订〈公司章程〉的 公告》（公告编号 2025-042）。 公司于近日完成了上述事项的变更登记和备案手续，并取得了珠海市市场监 督管理局发出的《登记通知书》。变更后具体登 ...

Group 1 - Baolite has experienced a decline for four consecutive trading days, with a cumulative drop of -5.33% [1] - Guangdong Baolite Medical Technology Co., Ltd. is a national high-tech enterprise engaged in the research, production, and sales of medical devices, covering three main business areas: life information and support, nephrology, and health care [1] - Jin Yuan Shun An Fund's Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund is among Baolite's top ten shareholders, having increased its holdings in the second quarter of this year [1] Group 2 - The Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund has achieved a year-to-date return of 31.54%, ranking 320 out of 2279 in its category [2] - The fund's performance over various periods includes a 2.81% increase over the past week, 3.89% over the past month, and 15.87% over the past three months [2] - The fund manager, Miao Weibin, has a background in economics from Fudan University and has held various positions in asset management prior to joining Jin Yuan Shun An Fund in October 2016 [3][4]

金融界消息 截至2025年8月19日收盘，宝莱特（300246）报收于9.79元，下跌2.0%，换手率10.3%，成 交量21.76万手，成交金额2.15亿元。 资金流向方面，今日主力资金净流出1572.14万元，占比成交额7.32%。其中，超大单净流出398.39万 元、占成交额1.85%，大单净流出1173.76万元、占成交额5.46%，中单净流出流出1390.69万元、占成交 额6.47%，小单净流入2962.84万元、占成交额13.79%。 天眼查商业履历信息显示，广东宝莱特医用科技股份有限公司，成立于1993年，位于珠海市，是一家以 从事研究和试验发展为主的企业。企业注册资本26368.3817万人民币，实缴资本26368.38万人民币。公 司法定代表人为燕金元。 通过天眼查大数据分析，广东宝莱特医用科技股份有限公司共对外投资了21家企业，参与招投标项目 970次，知识产权方面有商标信息58条，专利信息330条，此外企业还拥有行政许可179个。 来源：金融界 宝莱特最新一期业绩显示，截至2025中报，公司营业总收入5.23亿元、同比减少2.43%，归属净利润 131.34万元，同比增长152.22% ...

从资金流向来看，8月18日主力资金净流出2735.73万元，近五日主力资金累计净流出4192.67万元。 风险提示：投资有风险，入市需谨慎。本文所提及数据仅供参考，不构成投资建议。 来源：金融界 截至2025年8月18日收盘，宝莱特股价报9.99元，较前一交易日下跌1.48%。当日成交量为330852手，成 交金额达3.30亿元。 宝莱特属于医疗器械行业，主要业务涵盖医疗监护设备、血液透析设备等产品的研发、生产和销售。公 司产品广泛应用于医院、诊所等医疗机构。 根据最新披露的2025年中报，宝莱特实现营业总收入5.23亿元，归母净利润131.34万元，较去年同期实 现扭亏为盈。公司资产负债率为46.18%，较去年同期有所下降。经营活动现金流净额为-2474.65万元， 较去年同期有所改善。 ...

Core Insights - Baolite (300246.SZ) reported a total operating revenue of 523 million yuan for the first half of 2025, with a net profit attributable to shareholders of 1.3134 million yuan, an increase of 3.8284 million yuan compared to the same period last year [1] Financial Performance - The company's operating cash flow showed a net outflow of 24.7465 million yuan, which is an improvement of 13.6225 million yuan compared to the same period last year [1] - The latest debt-to-asset ratio stands at 46.18%, a decrease of 1.17 percentage points from the same period last year [3] - The gross profit margin is reported at 25.50% [3] - Return on equity (ROE) is at 0.11%, an increase of 0.30 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.01 yuan, an increase of 0.01 yuan compared to the same period last year [3] - The total asset turnover ratio is 0.21 times, remaining stable compared to the same period last year, with a year-on-year increase of 1.91% [3] - The inventory turnover ratio is reported at 1.62 times [3] Shareholder Structure - The number of shareholders is 18,400, with the top ten shareholders holding a total of 92.17 million shares, accounting for 34.84% of the total share capital [3] - The largest shareholder, Yan Jinyuan, holds 26.72% of the shares [3] - Other notable shareholders include Wang Shi (2.46%) and Shenzhen Qianhai Jiuyin Investment Fund Management Co., Ltd. (1.37%) [3]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it indicates a positive trend in the pharmaceutical and biotechnology sector with a weekly increase of 3.08% [3][8]. Core Insights - The pharmaceutical and biotechnology sector outperformed the Wind All A index and the CSI 300 index during the week of August 11 to August 15, with notable gains in medical research outsourcing (7.77%), hospitals (5.59%), and medical consumables (4.47%) [3][8]. - The upcoming launch of the commercial insurance innovative drug directory is expected to activate the domestic high-end payment market for innovative drugs, with 121 drug names passing preliminary review [3][8]. - The World Conference on Lung Cancer (WCLC) will take place from September 6 to 9, showcasing significant research advancements in lung cancer, with domestic research playing an increasingly important role [3][8]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 3.08%, outperforming the Wind All A index (2.95%) and the CSI 300 index (2.37%) [3][8]. - Medical research outsourcing, hospitals, and medical consumables led the sector's gains, while offline pharmacies, blood products, and medical circulation experienced declines [3][8]. - Notable individual stock performances included Sino Medical (69.1%), Innovation Medical (51.5%), and Guangsheng Tang (40.7%) for gains, while *ST Suwu (-16.8%), ST Sansheng (-15.2%), and Nanhua Biological (-14.2%) faced significant losses [3][11]. Industry News and Key Company Announcements - The National Medical Insurance Administration announced the preliminary review of the 2025 National Basic Medical Insurance drug directory and the commercial insurance innovative drug directory [3][13]. - Novo Nordisk received accelerated FDA approval for its therapy Wegovy for treating non-alcoholic steatohepatitis (NASH) [3][13]. - Yunnan Baiyao approved a full acquisition of An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for 660 million RMB to enhance its traditional Chinese medicine business [3][15]. - Insmed's DPP1 inhibitor Brensocatib received FDA approval for treating non-cystic fibrosis bronchiectasis [3][14].

Group 1 - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [3] - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period [5][6] - The company successfully completed the election of the new board of directors and the appointment of senior management personnel [8]

Financial Performance - The company reported total revenue of 523 million yuan, a decrease of 13.04 million yuan compared to the same period last year, representing a year-on-year decline of 2.43% [1] - The net profit attributable to shareholders was 1.31 million yuan, with net cash flow from operating activities at -24.75 million yuan [1] - The latest asset-liability ratio is 46.18%, an increase of 1.12 percentage points from the previous quarter [3] Profitability Metrics - The latest gross profit margin is 25.50%, down 1.89 percentage points from the previous quarter and down 2.17 percentage points year-on-year [3] - The return on equity (ROE) is 0.11% [3] - The diluted earnings per share (EPS) is 0.01 yuan [3] Efficiency Ratios - The total asset turnover ratio is 0.21 times [3] - The inventory turnover ratio is 1.62 times, a decrease of 0.18 times compared to the same period last year, representing a year-on-year decline of 9.89% [3] Shareholder Information - The number of shareholders is 18,400, with the top ten shareholders holding 92.17 million shares, accounting for 34.84% of the total share capital [3] - The largest shareholder is Yan Jinyuan, holding 26.72% of the shares [3]

Group 1 - The company Baolite announced on August 15 that its board of directors has approved the reappointment of Grant Thornton (special general partnership) as the auditing firm for the company's financial report and internal control for the year 2025 [2]

（文章来源：每日经济新闻） 宝莱特（SZ 300246，收盘价：10.14元）8月15日晚间发布半年度业绩报告称，2025年上半年营业收入 约5.23亿元，同比减少2.43%；归属于上市公司股东的净利润约131万元；基本每股收益0.005元。2024 年同期营业收入约5.36亿元；归属于上市公司股东的净利润亏损约251万元；基本每股收益亏损0.0095 元。 ...